The observed overall rate of EGFR alterations agrees well with the frequency of EGFR variants in European (non-Asian) NSCLC patients, as do the frequencies of the two most common EGFR alterations (exon 19 deletions, p.L858R), together accounting for 75.8% in the present study [15]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.